据介绍，APH03621片是一品红自主研发的一种新型口服、非肽类小分子促性腺激素释放激素受体拮抗 剂（GnRH-ant）。该药物作用机制针对GnRH受体，通过调节下丘脑-垂体-性腺轴，影响性激素水平， 从而治疗子宫内膜异位症。目前，国内暂无获批上市的GnRH口服小分子拮抗剂。 10月29日晚，一品红还在其官方微信公众号发布了AR882的最新动态，在10月24日至29日举行的2025年 美国风湿病学会年会（ACR Convergence 2025）期间，AR882最新临床结果以专题壁报《氘泊替诺雷 （AR882），单药治疗或与别嘌醇联合治疗初治及难治性痛风石患者的疗效》的形式发布并引发广泛热 议，展示了其在治疗痛风石患者II期试验中的良好治疗效果。 据介绍，AR882是一种新型高选择性URAT1抑制剂，目前正处于痛风和痛风石III期临床开发阶段。迄今 为止，只有静脉注射药物被批准用于难治性痛风患者降尿酸治疗，并通过游标卡尺测量和双能CT扫描 （DECT）显示了对痛风石的溶解效果。然而，对于大多数患者而言，由于治疗成本、药物可及性以及 需要伴随使用免疫抑制剂的潜在毒性，静脉注射治疗并不可用或不适用。 而一品红在研 ...

"2019年以来我国制定发布多个儿童用药相关指导原则，相关部门从保障需求、鼓励研发、优先审评、 简化采购程序、扩大医保支付范围等多个方面频繁出台了儿童用药相关政策，儿童药行业正在不断迎来 顶层设计与政策支撑。公司深耕儿童药领域，将持续依托自身在儿童药产品、技术等方面的储备，把握 政策机遇，进一步提高公众对儿童用药的重视度，打造具有核心竞争力的儿童药产品。"一品红 （300723）财务总监张辉星在2025年半年度业绩说明会上表示。 一品红是一家聚焦于儿童药、创新慢病药领域的创新型生物医药企业，是中国化药研发综合实力百强企 业、中国创新力医药企业100强和中国化药企业百强企业，也是广州生物医药产业链的链主企业。 一品红董事长兼总经理李捍雄在业绩说明会上介绍说，公司现有27个儿童药品注册批件，涵盖呼吸、消 化、皮肤等多个疾病领域，覆盖幼儿、儿童、青少年整个年龄阶段，可用于治疗儿童流感、感冒、感染 性疾病、功能性消化不良、手足口病、湿疹、心脑血管等多种临床需求迫切的常见疾病。目前，公司在 研管线还有16个儿童药项目，随着各项研究及申报注册工作有序推进，将会逐步投向市场。 今年以来，一品红在研1类痛风创新药AR882( ...

Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. was established in 2002, focusing on drug research, production, and sales, particularly in pediatric and chronic disease medications [2][3] - The company has a total of 204 drug registration certificates, including 90 national medical insurance varieties and 27 national essential drug varieties [3] Pediatric Drug Segment - Pediatric drug revenue accounted for 61.65% of the pharmaceutical manufacturing business, with a revenue of 357 million CNY in the first half of 2025 [3][4] - The company holds 27 pediatric drug registration certificates and has 16 pediatric drug projects under research, covering diseases such as epilepsy and influenza [4][5] - The company aims to enhance its market share in pediatric drugs by leveraging policy support and increasing public awareness [4] Research and Development - The company has approximately 60 ongoing research projects, including 14 innovative drug projects and 28 products pending approval [3] - The innovative drug AR882 has shown promising results in clinical trials, with all global Phase III clinical trial enrollments completed by August 2025 [5][6] Financial Performance - The company experienced a decline in revenue and net profit in the first half of 2025, attributed to industry conditions and internal business adjustments [6] - The company implemented stock incentive plans to motivate employees and enhance performance, granting over 5 million shares to 160 employees [6] Marketing and Sales Strategy - The company is focusing on expanding its marketing network across 31 provincial regions in China and enhancing its presence in new retail channels [7][8] - New product registrations are expected to positively impact sales, with 14 new drug registration certificates obtained in 2025 [6][7] Raw Material Production - The company has established a raw material drug base, which is expected to reduce costs and improve self-sufficiency in raw materials [9] - Currently, the company has 10 registered raw material drug numbers and 4 projects under research [9]

Core Insights - Yipinhong Pharmaceutical Group Co., Ltd. reported a steady development in the first half of 2025, focusing on children's medicine, chronic disease drugs, and innovative drugs [1] - The company achieved a revenue of 584 million yuan and a net profit attributable to shareholders of -73.54 million yuan in the first half of 2025 [1] - Total assets reached 4.981 billion yuan, reflecting a 13.1% increase compared to the beginning of the period [1] Financial Performance - Revenue for the first half of 2025 was 584 million yuan [1] - Net profit attributable to shareholders was -73.54 million yuan [1] - Total assets as of June 30, 2025, were 4.981 billion yuan, up 13.1% from the start of the year [1] R&D and Product Development - The company invested approximately 94.201 million yuan in R&D, accounting for 16.14% of total revenue [1] - A total of 10 new registration certificates were obtained, maintaining a leading position among pharmaceutical companies [1] - The company introduced 2 CMO projects and 1 equity investment project during the reporting period [1] Innovative Drug Progress - The innovative drug AR882 (Dezhuobote) is a selective URAT1 inhibitor with three indications: lowering blood uric acid for gout treatment, dissolving gout stones, and treating chronic kidney disease [2] - The global pivotal Phase III REDUCE 2 trial completed patient enrollment in March 2025, and the REDUCE 1 trial surpassed 50% enrollment by June 2025 [2] - The company acquired 15.25% of the equity in its subsidiary Guangzhou Ruianbo, increasing its ownership of AR882 in China to 100% [2]

Core Insights - The company Yipinhong (300723) reported a revenue of 584 million yuan and a net profit attributable to shareholders of -73.54 million yuan for the first half of 2025, indicating a focus on children's medicine, chronic disease drugs, and innovative drugs [1] - As of June 30, 2025, the company's total assets reached 4.981 billion yuan, an increase of 13.10% compared to the beginning of 2025 [1] - The company achieved significant progress in innovative drugs, obtaining 10 drug registration approvals in the first half of the year, with the global development of the innovative drug AR882 accelerating [1][2] Financial Performance - The company's revenue for the first half of 2025 was 584 million yuan, with a net loss of 73.54 million yuan [1] - Research and development investment for the first half of 2025 was approximately 94.21 million yuan, accounting for 16.14% of the company's revenue [1] Product Development - Yipinhong currently holds 200 drug registration approvals, including 87 national medical insurance varieties and 26 national basic drug varieties [2] - In the children's medicine sector, the company has 27 registration approvals covering common diseases such as respiratory, anti-infection, anti-allergy, and digestive issues [2] - In the chronic disease drug sector, there are 67 registration approvals addressing cardiovascular, urinary, and digestive system diseases [2] - The company also received 5 new product approvals in other therapeutic areas during the reporting period, expanding its product portfolio [2] Innovative Drug AR882 - AR882, developed in collaboration with Arthrosi, is a first-class innovative drug aimed at treating gout and gout stones by inhibiting uric acid reabsorption [2] - The drug's research results were presented at the 2025 European League Against Rheumatism (EULAR) conference, gaining international attention [2] - The global pivotal phase III REDUCE2 trial for AR882 has completed enrollment of all patients, while the REDUCE1 trial has surpassed 50% patient enrollment as of June 2025 [2]